Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8832027rdf:typepubmed:Citationlld:pubmed
pubmed-article:8832027lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:8832027lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:8832027lifeskim:mentionsumls-concept:C0021756lld:lifeskim
pubmed-article:8832027lifeskim:mentionsumls-concept:C0021747lld:lifeskim
pubmed-article:8832027lifeskim:mentionsumls-concept:C0035020lld:lifeskim
pubmed-article:8832027lifeskim:mentionsumls-concept:C0445550lld:lifeskim
pubmed-article:8832027lifeskim:mentionsumls-concept:C1512034lld:lifeskim
pubmed-article:8832027lifeskim:mentionsumls-concept:C0085973lld:lifeskim
pubmed-article:8832027lifeskim:mentionsumls-concept:C0007320lld:lifeskim
pubmed-article:8832027lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:8832027pubmed:issue1lld:pubmed
pubmed-article:8832027pubmed:dateCreated1997-2-27lld:pubmed
pubmed-article:8832027pubmed:abstractTextA patient, who was treated twice with donor lymphocyte infusions for relapse of CML after an allogeneic BMT was given lymphoblastoid human alpha-IFN after a third relapse. Further donor lymphocyte infusions were followed by repeated courses of 30 days treatment with a low dosage of IL-2 subcutaneously, alternately with alpha-IFN. This treatment resulted in a hematologic and cytogenetic remission. He also developed a limited degree of chronic GVHD. At the latest follow-up at 20 months after the third course of lymphocyte infusions he is in continuous hematologic and cytogenetic remission. Furthermore, a qualitative PCR analysis for the bcr/abl translocation is negative.lld:pubmed
pubmed-article:8832027pubmed:languageenglld:pubmed
pubmed-article:8832027pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8832027pubmed:citationSubsetIMlld:pubmed
pubmed-article:8832027pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8832027pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8832027pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8832027pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8832027pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8832027pubmed:statusMEDLINElld:pubmed
pubmed-article:8832027pubmed:monthJullld:pubmed
pubmed-article:8832027pubmed:issn0268-3369lld:pubmed
pubmed-article:8832027pubmed:authorpubmed-author:LönnqvistBBlld:pubmed
pubmed-article:8832027pubmed:authorpubmed-author:BruneMMlld:pubmed
pubmed-article:8832027pubmed:authorpubmed-author:LjungmanPPlld:pubmed
pubmed-article:8832027pubmed:issnTypePrintlld:pubmed
pubmed-article:8832027pubmed:volume18lld:pubmed
pubmed-article:8832027pubmed:ownerNLMlld:pubmed
pubmed-article:8832027pubmed:authorsCompleteYlld:pubmed
pubmed-article:8832027pubmed:pagination241-2lld:pubmed
pubmed-article:8832027pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:meshHeadingpubmed-meshheading:8832027-...lld:pubmed
pubmed-article:8832027pubmed:year1996lld:pubmed
pubmed-article:8832027pubmed:articleTitleLymphoblastoid human interferon and low dose IL-2 combined with donor lymphocyte infusion as therapy of a third relapse of CML--a case report.lld:pubmed
pubmed-article:8832027pubmed:affiliationDepartment of Hematology, Huddinge Hospital, Sweden.lld:pubmed
pubmed-article:8832027pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8832027pubmed:publicationTypeCase Reportslld:pubmed